Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony M Hunter

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Best Practice & Research. Clinical Haematology|October 11, 2020
Molecular genetics of MDS/MPN overlap syndromesAnthony M Hunter, Eric Padron
Expert Opinion on Pharmacotherapy|July 27, 2024
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literatureAnthony M Hunter, Prithviraj Bose
Best Practice & Research. Clinical Haematology|June 18, 2019
Current status and new treatment approaches in TP53 mutated AMLAnthony M Hunter, David A Sallman
Hematology/Oncology Clinics of North America|February 25, 2020
Targeting TP53 Mutations in Myelodysplastic SyndromesAnthony M Hunter, David A Sallman
Current Treatment Options in Oncology|October 28, 2018
Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic LeukemiaAnthony M Hunter, Ling Zhang, Eric Padron
Clinical Lymphoma, Myeloma & Leukemia|October 2, 2024
SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in MyelofibrosisMichael J Hochman, Colin A Vale, Anthony M Hunter
Current Hematologic Malignancy Reports|October 8, 2025
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia VeraMinghui Duan, Prithviraj Bose, Anthony M Hunter, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2025
Risk factors, behaviors, and adverse health outcomes of financial toxicity in adult chronic myeloid leukemia survivors: a theory-based structural equation modelRuiqi Jin, Sudeshna Paul, Sarah M Belcher, et al.
Blood|November 7, 2024
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigmAnthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, et al.
Blood Advances|February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromesAnthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Best Practice & Research. Clinical Haematology|October 11, 2020
Molecular genetics of MDS/MPN overlap syndromesAnthony M Hunter, Eric Padron
Expert Opinion on Pharmacotherapy|July 27, 2024
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literatureAnthony M Hunter, Prithviraj Bose
Best Practice & Research. Clinical Haematology|June 18, 2019
Current status and new treatment approaches in TP53 mutated AMLAnthony M Hunter, David A Sallman
Hematology/Oncology Clinics of North America|February 25, 2020
Targeting TP53 Mutations in Myelodysplastic SyndromesAnthony M Hunter, David A Sallman
Current Treatment Options in Oncology|October 28, 2018
Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic LeukemiaAnthony M Hunter, Ling Zhang, Eric Padron
Clinical Lymphoma, Myeloma & Leukemia|October 2, 2024
SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in MyelofibrosisMichael J Hochman, Colin A Vale, Anthony M Hunter
Current Hematologic Malignancy Reports|October 8, 2025
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia VeraMinghui Duan, Prithviraj Bose, Anthony M Hunter, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2025
Risk factors, behaviors, and adverse health outcomes of financial toxicity in adult chronic myeloid leukemia survivors: a theory-based structural equation modelRuiqi Jin, Sudeshna Paul, Sarah M Belcher, et al.
Blood|November 7, 2024
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigmAnthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, et al.
Blood Advances|February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromesAnthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
Pageof 2